Xencor Analyst Price Targets - Benzinga

Xencor Inc

XNCRNASDAQ

Trade with Public

Trade with Public

$29.21

-0.78-2.6%

Últ. Act.: Oct 29, 5:38 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Xencor Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xencor (XNCR).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

1S.Buy

12Buy

2Hold

Consensus RatingOverweight# Analysts15Avg. Consensus PT$35Upside to Avg. PT+18.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$29→$40
Oct 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$20→$43
Oct 27, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$30→$44
Oct 27, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$30→$45
Oct 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$30
Sep 28, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$27→$29
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Neutral	$20→$26
Sep 11, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$27→$35
Sep 3, 2026	JP Morgan	Brian Cheng	PT Raise	Neutral	$14→$21
Sep 1, 2026	Raymond James	Sean McCutcheon	PT Raise	Strong Buy	$40→$46
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$19→$20
Aug 6, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$26→$30
Aug 6, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$43→$44
Jul 30, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$26
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$29→$27
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Neutral	$13→$14
Mar 24, 2026	JP Morgan	Brian Cheng	Downgrade	Overweight→Neutral	$18→$13
Feb 26, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$26→$27
Dec 17, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$23→$26
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$29

Analyst Ratings News

PRO
Truist Securities Maintains Buy on Xencor, Raises Price Target to $40

Truist Securities analyst Gregory Renza maintains Xencor (NASDAQ:XNCR) with a Buy and raises the price target from $29 to $40.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Xencor, Raises Price Target to $43

RBC Capital analyst Leonid Timashev maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $20 to $43.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Xencor, Raises Price Target to $44

Wells Fargo analyst Derek Archila maintains Xencor (NASDAQ:XNCR) with a Overweight and raises the price target from $30 to $44.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Xencor, Raises Price Target to $45

Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $30 to $45.

Benzinga Newsdesk

Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.

Vandana Singh

PRO
Wedbush Reiterates Outperform on Xencor, Maintains $30 Price Target

Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $30 price target.

Benzinga Newsdesk